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ARTICLE
Development of high-throughput ATR-FTIR
technology for rapid triage of brain cancer
Holly J. Butler1,2*, Paul M. Brennan3, James M. Cameron1, Duncan Finlayson1, Mark G. Hegarty2,
Michael D. Jenkinson4, David S. Palmer 1,2, Benjamin R. Smith1 & Matthew J. Baker1,2*
Non-speciﬁc symptoms, as well as the lack of a cost-effective test to triage patients in
primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain
cancer patients. A rapid, cost-effective, triage test could signiﬁcantly improve this patient
pathway. A blood test using attenuated total reﬂection (ATR)-Fourier transform infrared
(FTIR) spectroscopy for the detection of brain cancer, alongside machine learning technology,
is advancing towards clinical translation. However, whilst the methodology is simple and does
not require extensive sample preparation, the throughput of such an approach is limited. Here
we describe the development of instrumentation for the analysis of serum that is able to
differentiate cancer and control patients at a sensitivity and speciﬁcity of 93.2% and 92.8%.
Furthermore, preliminary data from the ﬁrst prospective clinical validation study of its kind
are presented, demonstrating how this innovative technology can triage patients and allow
rapid access to imaging.
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The symptoms experienced by patients with a brain tumourare often non-speciﬁc and are more frequently associatedwith a benign non-tumour condition1. Headache, the most
common symptom of brain tumours in adults2, also occurs in
4.4% of all primary care consultations3. Timely diagnosis of a
brain tumour is therefore challenging. Brain tumours are the
commonest cancer type to be diagnosed as an emergency pre-
sentation in the UK1, and many of these patients will have already
seen their general practitioner (GP) several times.
It is difﬁcult to determine which patients with non-speciﬁc
symptoms are most at risk of having a brain tumour and should
be prioritised for urgent medical imaging4. The best performing
symptom-based referral guidelines for suspected brain tumour
only expect to identify a brain tumour at a frequency of
approximately 3% in the referral population. New strategies are
needed to support decision making, particularly in primary care5.
A blood test at this point in the pathway could facilitate stra-
tiﬁcation of patients deemed at risk based on their symptoms,
prioritising patients for urgent brain imaging (Fig. 1). It has been
reported that the prevalence of brain tumours in this at risk
population is as low as 1.6%, so a large proportion of scans are
unnecessary6,7.
Attenuated total reﬂectance–Fourier transform infrared
(ATR-FTIR) spectroscopy is a simple, label free, non-invasive,
non-destructive analytical technique that can characterise the
biochemical proﬁle of a sample without extensive sample pre-
paration. By interrogating biological samples with infrared (IR)
light, it is possible to elucidate a speciﬁc biochemical ﬁngerprint.
ATR-FTIR spectroscopy has therefore demonstrable potential as
a powerful diagnostic tool8. The interrogation of bioﬂuids such as
blood (and its derivatives, serum and plasma), can provide a
systemic snapshot of the human body9 and reported diagnostic
applications have included detection of malaria10, Alzheimer’s
disease11, and a variety of cancers, including; ovarian12, color-
ectal13, lung14, and brain15.
In the brain tumour population, a comparison of blood serum
has been made between patients with glioma and non-cancer
patients16, between patients with high grade (glioblastoma) and
low grade gliomas17, and in the largest study to date, samples
from 433 patients explored a range of primary (glioma, menin-
gioma) and secondary (metastatic) brain cancers15. These studies
were performed on retrospective biobank collections of blood.
The diagnostic output is generated by machine learning algo-
rithms, which learn the differences in IR signatures that are
indicative and exclusive to cancer. Much of the progression in this
area is centred around these computational approaches which
require ﬁne tuning18–20. Based on these retrospective studies, the
blood test yielded has a sensitivity and speciﬁcity for brain
tumour of 92.8% and 91.5% respectively, using a traditional ATR-
FTIR spectrometer conﬁguration.
Conventionally, an ATR-FTIR spectrometer has a single point
of analysis, the internal reﬂection element (IRE) is made from a
material with a high refractive index, such as diamond, germa-
nium, or zinc selenide. The serum sample, with a lower refractive
index, is deposited directly onto the surface of the IRE21. IR light
enters the IRE and is internally reﬂected, resulting in the for-
mation of an evanescent wave at the IRE-sample interface. It is
this wave that interrogates the samples at a deﬁned penetration
depth (calculable dependent upon refractive indices of the IRE
and sample, the wavelength of IR beam, and the angle of inci-
dence)22.
The primary limitation of the IRE is that they are usually high
cost, inhibiting the production of an instrument with high-
throughput capabilities. This has resulted in an inﬂexible tech-
nology, with a ﬁxed point of analysis and no capacity for batch
processing. The IR transparency and relative low-cost of
engineering makes Silicon (Si) an ideal material for IREs23. For IR
studies, Si IREs are not usually favoured due to Si lattice vibra-
tions presenting within the biologically relevant ﬁngerprint
region, obscuring information below 1500 cm−1 wavenumbers24.
These occur often due to larger sized crystals, as well as multi-
bounce systems. Similarly to the phenomena of ATR-FTIR
spectroscopy overcoming water absorption, by reducing the
pathlength of the IR beam through the Si IRE, the contributions
of the Si lattice vibrations can be minimised25. Microfabricated Si
IREs may allow single bounce internal reﬂections, effectively
minimising the IR beam pathlength and circumventing unwanted
spectral contributions from Si.
The technical considerations inherent in applying this test in
real-time in the clinic have been explored in great detail,
including the examination of sample handling26,
preparation17,27,28, and an investigation into the mechanisms of
serum deposition patterns that may inﬂuence the spectral
response29. The integration of the test into a clinical pathway has
also been assessed30.
In our proposed pathway for patients with suspected brain
tumours (Fig. 1) the result derived by ATR-FTIR spectroscopy is
not used as an absolute diagnostic, rather a triage tool, which
provides the GP with additional information to inform their
referral decision31. We develop disposable Si IRE sample slides
that allow the rapid preparation and analysis of multiple samples,
enabling high-throughput ATR-FTIR spectroscopy optimised for
clinical research (Fig. 2). These can be purchased at the fraction of
a cost of a traditional IRE. Based upon the design of a microscope
slide, these optical sample slides contain a Si IRE with four sample
areas; one for background measurements and three for repeat
measurements of a single patient. This device is developed for the
triplicate measurement of patient samples with optimised spectral
throughput and performance. We describe the transition to this
technology for the established application of ATR-FTIR spec-
troscopy of blood serum for the detection of brain cancer, and the
subsequent impact on clinical translation. This technological
advance has led to a prospective clinical validation study in the
target population, the interim analysis is presented here. The
translation of this blood test for the early detection of brain
cancer into to the clinic depicts both a technological step and a
step towards to improving the clinical pathway for patients with
this disease.
Results
Si IRE evaluation. Deﬁned arrays of v-grooves were successfully
microfabricated onto Si wafers. These arrays deﬁne the optically
active region of the Si IRE, where serum is deposited and sub-
sequently analysed using IR light. The etched surface of the Si IRE
is IR beam facing, so that light is coupled through the Si IRE
parallel to the direction of the grooves (Fig. 3).
The etching process is highly accurate, with etching efﬁciencies
ensuring that optical features of the Si IREs are accurate within
error margins below 2%. This minimises the risk of increased
spectral variability that may arise due to inconsistencies in the
optically active regions of the disposable IRE. An in-house
derived protocol has been developed to quality test freshly
produced Si IREs, ensuring that the background energy spectrum
falls within a deﬁned acceptance range.
To explore the analysis of human blood serum, the spectral
output of Si IREs were compared against conventional ATR-FTIR
spectroscopy using a diamond IRE (Fig. 4). In this example,
human pooled serum was analysed to remove biological variation.
Spectra derived from Si IREs display increased variation between
spectra, shown by larger standard deviation shading surrounding
the mean spectrum. This is predominantly visible between 2700
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Fig. 1 Proposed integration of a blood test for the triage of brain cancer. Lack of speciﬁc symptoms often results in brain cancer patients visiting their GPs
numerous times before receiving a diagnosis; a blood test in primary care could effectively prioritise patients for urgent brain imaging, potentially reducing
the time-to-diagnosis. The ATR-FTIR spectroscopy test would ﬁt into standard blood analysis
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and 2000 cm−1 wavenumbers, although few biological peaks are
present in this region of the spectrum. The ﬁngerprint region
(1800–1000 cm−1) is considered the region of biological interest
and marginal increases in variation are visible, although not
signiﬁcantly more than diamond obtained spectra. Some spectral
features differ slightly between the two IREs; noticeably, the
shoulder of N–H protein band (3500–3300 cm−1), the ratio
between the amide I and amide II peaks, and contributions from
the Si lattice vibrations (1100 cm−1).
Retrospective patient cohort. A 724 retrospective patient cohort
was investigated to assess the diagnostic performance of Si IRE
based ATR-FTIR spectroscopy. This cohort contains a range of
primary and secondary brain cancers as well as control (non-
cancer) patients (Table 1). Glioblastoma multiforme (GBM) is the
largest primary cancer group in this study, reﬂecting the higher
incidence of this tumour class. Where possible patients have been
age and sex matched between both disease groups, whilst also
taking into account the natural disease prevalence (Table 2)32. An
Labelled sticker
Si IRE
Plastic IRE holder
Fig. 2 Expanded view of optical sample slides. Silicon internal reﬂection elements (Si IREs) are sandwiched between a 3D printed plastic holder and a
medical grade labelled sticker. The latter deﬁnes the optically active regions of the Si IRE, split into four wells, three used for triplicate sample analysis and
one for a background measurement. The fully assembled slide measures 75mm × 25mm, mimicking standard microscope slides
a
b
c
Fig. 3 Schematic representation of Si IREs for clinical spectroscopy. a Sample-side, b IR facing side, c v-groove detailing (not to scale)
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Fig. 4 Human pooled serum spectrum obtained from Si IRE ATR-FTIR spectroscopy. Coloured shading represents standard deviation of ten spectra derived
from Si (blue) and diamond (red) IREs
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age-matched subset of this cohort (n= 226) was also analysed in
order to ensure that any differentiation between disease groups is
associated with cancer presence only (Supplementary Table 1 and
Supplementary Fig. 3).
Using machine learning, it is possible to predict disease status
from spectral data by training a model on a known dataset
(known as supervised learning), and subsequently testing on a
blind test dataset. The prediction results from a support vector
machine (SVM) classiﬁcation are presented here, and are
indicative of the potential predictive power of ATR-FTIR
spectroscopy coupled with machine learning. Binary classiﬁcation
between cancer and non-cancer is explored primarily to portray
the suggested use as a triage tool. A prediction is made for each of
the nine spectra from a single patient and the majority vote is
taken as the diagnostic prediction for that patient (cancer or non-
cancer). The accuracy of the classiﬁer can be deduced by
observing the number of correct and incorrect predictions for an
external test set containing data that was not used in training the
algorithm (Fig. 5). On a per patient basis, and averaged over
51 randomised training and test set splits, the sensitivity and
speciﬁcity of the approach computed for the test set is 93.2%
and 92.0% respectively, indicating potential to detect both cancer
and control patients effectively. When considering an age-
matched subset of this cohort, an equally high sensitivity and
speciﬁcity of 89.5% for both metrics indicates this promising
performance is likely associated with disease differentiation
speciﬁcally, as opposed to a difference in cohort age or sex. The
area under the curve (AUC) of this model, as derived from the
receiver operating characteristic (ROC) curve (Supplementary
Fig. 2) has a value of 0.96, which can be considered excellent.
Table 1 Retrospective patient cohort breakdown with tumour classiﬁcation details
WHO classiﬁcation Tumour type WHO grade Total
Tumour
Diffuse astrocytic and oligodendroglial tumours Glioblastoma multiforme IV 260
Gliosarcoma IV 4
Oligodendroglioma II 11
Diffuse astrocytoma II 23
Anaplastic astrocytoma III 10
Oligoastrocytoma II 3
Glioma I 7
Other astrocytic tumours Pilocytic astrocytoma I 9
Pleomorphic xanthoastrocytoma II 1
Tumours of the cranial and paraspinal nerves Schwannoma I 14
Ependymal tumours Ependymoma II 6
Mesenchymal, non-meningothelial tumours Haemangiopericytoma II/III 2
Haemanglioblastoma I 1
Neuronal and mixed neuronal-glial tumours Ganglioglioma I 1
Embryonal tumours Medulloblastoma IV 1
Tumours of the pineal region PPTID II/III 1
Meningiomas Meningioma I 46
Pituitary tumours Pituitary adenoma 29
Lymphomas Lymphoma 2
Metastatic tumours Metastasis 56
Control 237
Total 724
Table 2 Retrospective patient cohort information
Cancer Non-cancer
Total 487 237
Sex (M/F) 280/207 149/84
Age range 21–96 19–69
Average age 61 35
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Fig. 5 Disease prediction of blood serum using ATR-FTIR spectroscopy
coupled with SVM classiﬁcation. a Confusion matrix of classiﬁcation on a
per patient basis with b confusion ball visualisation of sensitivity and
speciﬁcity. All data refer to resampled and averaged test set predictions
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Prospective clinical validation study. With promising results
obtained from a retrospective patient dataset, the suitability of the
test in a clinical setting was assessed in a prospectively recruited
patient cohort. Patients referred from their GP for brain imaging
to exclude a brain tumour were recruited, along with patients
with a recent diagnosis of a new brain tumour admitted to the
neurosurgical unit. The outputs from this study were two-fold;
ﬁrstly, a blinded analysis of the trained patient algorithm and
secondly, a better understanding of unknown patient variance
that can arise from prospective cohorts.
For this process the previously described SVM algorithm,
trained on the 724 retrospective cohort, was used to predict the
disease status of 104 test patients recruited as part of prospective
clinical validation study (Fig. 6), in the ﬁrst interim analysis of
the cohort. Throughout this process, the analysis was blinded to
the imaging outcome until the algorithm result had been
reported. The reported sensitivity of 83.3% and speciﬁcity of
87.0% display noticeable reductions when compared to retro-
spective patient results. This initially would suggest diminished
ability to detect patients with or without cancer; however, the
value for sensitivity falls above the thresholds for cost-
effectiveness already deﬁned33. The same can also be said for
speciﬁcity, where a value above 80% indicates the test would
provide cost savings to the UK and US health services when used
as a triage tool in secondary, as well as primary care.
Within this prospective patient cohort, a total of 12 patients
were observed to have cancer. The tumour type breakdown
included; four GBM, three anaplastic astrocytoma, two oligoas-
trocytoma, one medulloblastoma, one ependymoma and one
gliosarcoma. It is clear in Table 1 that some of these tumour
classiﬁcations are not well represented in the training dataset and
could thus be the source of unwanted false negative predictions.
For example, the ependymoma case was incorrectly identiﬁed as
non-cancer (data not shown) and only six incidences of this
tumour class are found in the 724 patient training dataset.
Discussion
A simple test for the early diagnosis of brain cancer in primary
care has the potential to make dramatic impacts on patient sur-
vival and quality of life, whilst also saving resources and costs
within health services across the world15. Analysis of blood serum
using ATR-FTIR spectroscopy is a technique advancing towards
the clinic, aiming to ﬁll the void as a triage tool to help inform GP
referral decisions33. Up until now, the technique has been limited
by low-throughput technology that requires near constant user
attention, potentially inhibiting clinical uptake. Disposable, Si
IREs transform conventional ATR-FTIR spectroscopy by allow-
ing batch processing of samples, and conversion of commercial
spectrometers into high-throughput analysers.
Integration of Si IREs into spectrometers is simpliﬁed by patent
pending technology; optimised design of the Si IRE holder allows
easy handling, and an indexing unit guides the slide across the
open aperture of the spectrometer. The spectral output of Si IREs is
of equivalent quality to that of convention IRE materials, such as
diamond, without exhibiting strong spectral features from the Si
itself. Whilst there is increased variability between spectra obtained
with Si IREs, this is minimal for an approach where the back-
ground reference spectrum is taken from essentially a separate IRE.
Differences between diamond and Si IREs can be attributed to
differing baselines as a consequence of the grooved under surface;
however, this can be modelled using iterative processes.
The classiﬁcation performance of the Si IREs on a retrospective
dataset is also equivalent to previously reported data on diamond.
The 724 patient cohort analysed using Si IREs obtained a sensi-
tivity and speciﬁcity of 93.2% and 92.8% respectively, compared
to 92.8 and 91.5% on a retrospective 433 patient cohort18. In both
these examples, a SVM-based classiﬁcation protocol was used to
extract the signals of primary and secondary brain cancers.
Although the patient cohorts were comprised of separate patients
and thus not entirely comparable, the high diagnostic capability is
positive. Improved sensitivity of the technique may occur as a
consequence of altering the IRE material and thus the penetration
depth of the evanescent wave, or due to accounting for more
variance in the patient population.
With conﬁrmation of diagnostic performance on Si IREs, the
retrospective dataset is fundamental to predictions of prospective
patients. By training a classiﬁcation algorithm on this known
population, blind data can be predicted based upon the derivation
of cancer signals from the dataset. This approach would mimic the
real-world application of the blood test and is thus an appropriate
measure of true diagnostic accuracy. The ﬁrst prospective study
employing ATR-FTIR spectroscopy is presented here; an interim
analysis of an ongoing prospective validation study.
A sensitivity of 83.3% shows the huge clinical potential of this
test, effectively identifying those patients who desperately need
brain scans. From a patient perspective, higher sensitivity has the
greatest impact on quality of life due to the opportunity to
identify and treat cancers early34. From an economic perspective,
a test with high speciﬁcity is desirable as the number of unne-
cessary brain scans can be reduced; estimated to be in the region
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Fig. 6 Disease prediction of a prospective patient cohort with suspected
brain cancer using ATR-FTIR spectroscopy. Blind analysis was conducted
using an SVM algorithm previously trained on retrospective patient cohort.
a Confusion matrix of classiﬁcation on a per patient basis with b confusion
ball visualisation of sensitivity and speciﬁcity
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of £6–12 million every year in the UK alone33. At a speciﬁcity of
87.0%, the introduction of an ATR-FTIR spectroscopy based
blood test in primary care would deliver signiﬁcant cost savings to
the health services.
It is important to note, that this preliminary clinical data
provides an early insight into the diagnostic accuracy of this
blood test, with the caveats of small patient numbers (n= 104)
which limits the obtainable values of sensitivity and speciﬁcity.
Considering the data with regards to the potential reduction in
unnecessary brain scans, in this cohort of 104 patients, only 12
patients would be referred to secondary care. Taking into account
the health economic argument that 50% of patient would still be
referred by their GP, regardless of the spectroscopic blood test
result, this would still result in a 44% reduction in the number of
brain scans33.
This work presents a step in the translation of ATR-FTIR
spectroscopy into the clinic. This step towards high-throughput
analysis has implications in the ﬁeld of IR spectroscopy as well as
the clinical environment. Analysis of blood serum using this
technique would ﬁt ideally in the clinical pathway as a triage tool
for brain cancer. For the effective treatment of this disease, it is
essential to identify tumours early—A need presently unmet by
the current diagnostic pathway. A triage tool available in primary
care would provide GPs with further information to inform their
referral decision; providing at risk patients access to imaging in
secondary care, whilst also providing reassurance to those
patients who are not at risk. Consequently, time-to-diagnosis for
brain cancer patients could be reduced whilst also bringing cost
beneﬁts to the health services.
Methods
For thorough understanding of this issue, we direct the reader to key literature
regarding instrumentation and theory of ATR-FTIR spectroscopy8,22,35.
Si IRE production. Si IREs were designed in-house, and optimised for spectral
collection in the mid-IR wavelength region between 2.5 and 25 µm. Dimensions of
the Si IREs were chosen based on optimum light throughput, spectral quality and
reproducibility. An array of v-grooves are etched into the IR facing surface using
conventional anisotropic wet etching following the stages of photomask design,
hard mask deposition, application of photoresist and hard mask etching. Upon
etching, Si wafers are diced into individual four-well Si IREs. These Si IREs are
placed into plastic IRE holders, developed and 3D printed in-house, and held in
place with an adhesive top layer, that also deﬁnes the deposition areas on the
sample surface (Fig. 2). Once assembled, this constitutes the optical sample slide.
A custom built translational stage was constructed that interfaces optical sample
slides with commercially available FTIR spectrometers. These stages can be
automated to further improve throughput, reducing the personnel resource
required.
Retrospective patient cohort. To compare the spectral, and thus diagnostic,
capabilities of Si IREs with traditional IREs a large cohort retrospective study was
conducted on control and cancer patients. Samples were obtained from three
sources; the Walton Centre NHS Trust (Liverpool), Royal Preston Hospital (Pre-
ston), and also from the commercial source Tissue Solutions Ltd (Glasgow, UK).
Ethical approval for this study was obtained (Walton Research Bank BTNW/
WRTB 13_01/ BTNW Application #1108) and informed consent was obtained
from all patients prior to serum collection. Inclusion criteria for cancer patients
were as follows: (1) patients with pathologically conﬁrmed primary or secondary
brain cancers, (2) no chemo- or radio-therapy at the time of tissue sampling. For
control patients, inclusion criteria stated that the person should have no history of
cancer, or be undergoing any medical treatments. A total of 724 patients were
included in this study. Blood samples were obtained in S-Monovette (Sarstedt,
Germany) collection tubes and allowed to clot for up to one hour, before being
centrifuged at 2200 × g for 15 min at room temperature. Serum was subsequently
aliquoted and frozen at −80 °C until the time of analysis.
Prospective clinical study. To compare the diagnostic accuracy of the blood test,
including hardware and software, a prospective validation study was established at
the Western General Hospital, Edinburgh, with local ethical approval (2017/0320/
SR938, 15/ES/0094). Informed consent was obtained from all patients prior to
serum collection. Lothian region patients were eligible if suspected of having a
brain tumour by their GP and referred directly for brain imaging through the local
open access CT (OACT) service. This is most closely representative of the target
patient cohort for our triage blood test. The criteria for GPs to access the OACT
pathway is simply that their assessment that a patient’s symptoms necessitate
urgent brain imaging; patients requiring emergency imaging are referred to the
Emergency Department or indeed via a stroke referral pathway. As such these
patients represent a cohort of patients the GP has selected for referral brain ima-
ging. Patients referred via the OACT route for brain imaging were eligible to take
part in this validation study provided they were able to give informed consent.
Patients with a new brain tumour diagnosis referred to the neurosurgical unit for
assessment were also eligible for inclusion. Analysis of the blood samples with our
strategy was blinded to the whether the patient had a brain tumour or not. Sample
handling protocols were consistent with those from the retrospective patient cohort
previously mentioned.
The study was developed to have an adaptive design, to ensure that the
optimum number of patients was recruited to enable assessment of test sensitivity
and speciﬁcity. For initial sample size estimates (80% power, 5% signiﬁcance level),
to estimate speciﬁcity within 5% required a sample size between 200 and 600
assuming 2% prevalence (or 98% without brain tumour) for an assumed speciﬁcity
in the range of 95% (n= 188) to 75% (n= 622). For the sensitivity, to demonstrate
90% sensitivity to within 30% requires 400 subjects (3% prevalence) or 600 (2%
prevalence); note speciﬁcity was 91% in our previous study. The sample size was
planned to be calibrated throughout the study by scheduled interim sample analysis
and the cohort presented here is the ﬁrst patient group from the larger study to be
analysed. With a prevalence of 1–3% of actual brain tumours amongst imaged
patients, we expected to generate evidence on speciﬁcity (true negatives and false
positives) far more quickly than for sensitivity (true positives and false negatives).
An estimate of the overall speciﬁcity of the blood test was made by correlating the
predicted diagnosis with the gold standard (brain imaging, and biopsy where
necessary). This interim analysis was made within the adaptive element of the
design to assess how many additional samples would be needed in the full study to
estimate speciﬁcity. Supplementary Fig. 1 shows a consort ﬂow diagram of the
validation study and Supplementary Table 2 shows the demographic data for
patients that either accepter or declined to be part of the study to highlight the
unbiased approached to patient recruitment.
Sample preparation. Serum samples were thawed at room temperature (18–25 °C)
for a minimum of 15 min. Serum was deposited onto the three sample wells of the
optical sample slide, ensuring that the background well remains empty. Prepared
slides are placed in a drying unit (Thermo Fisher Heratherm, GE) Incubator at 35 °C
for 1 h, providing even heat and airﬂow for controlled drying dynamics of the
serum droplet29.
Spectral collection. The optical sample slides act as both a sample substrate and a
versatile IRE for IR spectroscopy, and can be easily interfaced with commercial
spectrometers. For this study, a specular reﬂectance accessory combined with the
optical sample slides replaces traditional IREs. A purpose built ‘Slide Indexing
Unit’—a simple slide carriage connected to a linear motor—allows accurate
movement across the spectrometer aperture, indexing the optical sample slide
between wells. This automated unit can ultimately provide high-throughput ana-
lysis, that does not require constant attention from technical staff. Spectra were
collected using optimum spectrometer parameters for Si IREs, deﬁned in this
instance as 4 cm−1 resolution (with 1 cm−1 data spacing) and 16 co-added scans.
Spectral analysis. Data handling is fundamental to this technology, and forms a
critical part of intellectual property and know-how regarding Si IREs for clinical
use. In short, spectral analysis can be divided into spectral pre-processing and
spectral classiﬁcation; the former reducing unwanted variance in the dataset and
the latter performing the disease prediction step.
For pre-processing, a combination of baseline correction, normalisation and
data reduction enables the signiﬁcant biological information, in this case disease
status, to be revealed and improves the classiﬁcation performance20. The optimum
pre-processing protocol was determined using a trial-and-error iterative approach
and is speciﬁc to Si IRE analysis.
For the spectral classiﬁcation, machine learning techniques were applied to the
spectral datasets. The purpose of this approach is to identify the signals of cancer
from a known patient cohort to develop a trained classiﬁcation model, and then to
use this information to predict the presence of cancer in an unknown population;
as per the real-world application. In this instance, the retrospective patient cohort
would form the ‘Training’ dataset and the prospective patient cohort would form
the external ‘Testing’ dataset. In this study we present the use of a SVM learning to
extract spectral patterns indicative of cancer. SVMs are supervised techniques that
construct a hyperplane through data projected in a high dimensional space,
allowing classiﬁcation of spectra and or patient data36.
To train the classiﬁcation models, patients from the retrospective patient cohort
were randomly split into training (70%) and test (30%) portions. No single patient
can appear in both of these portions. Algorithmic parameters were tuned using a
grid search to maximise Kohen’s Kappa computed on a per-spectra basis for ﬁve
fold cross validation on the training set. The tuned model was then used to make
predictions for the spectra in the external test set. Each of the nine spectra
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generated per patient was analysed independently, with the consensus vote
amongst the spectra reported as the diagnostic outcome (cancer or non-cancer).
The whole process was iterated 51 times to obtain adequate sampling for
summative statistics. The performance metrics, such as sensitivity and speciﬁcity,
that are reported in the Results section were derived based on the number of
correct and incorrect predictions for the external test set only.
To then predict the prospective patient cohort, the iterated machine learning
algorithm(s) were again trained on the training portion of the 724 retrospective
patient cohort, internally validated using the test set, and subsequently applied to a
blind external test set; in this case, the prospective patient cohort. The diagnostic
outcome for each patient was reported as the consensus vote of all predictions.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated and/or analysed during the current study are available within the
article and Supplementary Information ﬁles and available from the authors upon
reasonable request.
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